Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094067 · ClinicalTrials.gov registry record · Phase 2
Tezosentan in Patients With Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01094067 is a Phase 2 study that was terminated before completion, run by Idorsia Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT01094067, a Phase 2 study, was terminated before completion, sponsored by Idorsia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.
Interventions
- OTHER Placebo
- DRUG ACT-050089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-09-01 |
| Est. Completion | 2011-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094067
The ClinicalTrials.gov registry entry for NCT01094067 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01094067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01094067 about?
NCT01094067 is a clinical study titled "Tezosentan in Patients With Pulmonary Arterial Hypertension". Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a com...
What is the current status of trial NCT01094067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-09-01. Estimated completion is 2011-09-01.
What interventions are being tested in trial NCT01094067?
The interventions under investigation include: Placebo (OTHER), ACT-050089 (DRUG).
Who is sponsoring clinical trial NCT01094067?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.